BC
PHIO icon

Broadfin Capital’s Phio Pharmaceuticals PHIO Stock Holding History

Broadfin Capital’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5
Closed -$585K – 67
2016
Q3 		$585K Sell
5
-3
-38% -$405K 0.05% 69
2016
Q2 		$1.17M Hold
8
– – 0.11% 67
2016
Q1 		$1.35M Sell
8
-1
-11% -$176K 0.13% 66
2015
Q4 		$1.96M Sell
9
-1
-10% -$251K 0.12% 83
2015
Q3 		$2.27M Hold
10
– – 0.13% 79
2015
Q2 		$3M Buy
10
+8
+400% +$2.69M 0.16% 85
2015
Q1 		$811K Hold
2
– – 0.06% 81
2014
Q4 		$1.8M Hold
2
– – 0.16% 72
2014
Q3 		$2.25M Hold
2
– – 0.24% 67
2014
Q2 		$3.4M Hold
2
– – 0.33% 59
2014
Q1 		$4.81M Buy
+2
New +$6.35M 0.47% 51

Other funds holding PHIO

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Broadfin Capital's PHIO Position: Q4 2016 in Review

Broadfin Capital sold out of Phio Pharmaceuticals (PHIO) in Q4 2016, closing a stake of 5 shares — an estimated $585K sold.

Broadfin Capital first reported a position in PHIO in Q1 2014 and held it in 11 quarters. The position peaked at $4.81M in Q1 2014. 5 funds tracked by Wall St. Rank hold PHIO as of Q4 2016.

  • Broadfin Capital reported no remaining Phio Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Broadfin Capital sold 5 Phio Pharmaceuticals shares in Q4 2016, an estimated $585K.
  • Broadfin Capital first reported a position in Phio Pharmaceuticals in Q1 2014 and held it in 11 quarters.
  • Broadfin Capital's Phio Pharmaceuticals position peaked at $4.81M in Q1 2014.
  • 5 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q4 2016.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.